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Executive Summary
Medicalisation is defined by the World Health Organization as a situation in which female genital
mutilation/cutting (FGM/C) “is practiced by any category of health-care provider, whether in a public
or private clinic, at home, or elsewhere” (WHO, 2010: 2). Despite the emergence of international
consensus that female genital mutilation/cutting (FGM/C) is a violation of human rights, a focus on
medicalisation remains salient because of concerns that FGM/C is increasingly being performed
by healthcare professionals and may be impeding progress toward abandonment of FGM/C. To
investigate these claims, this study draws on nationally-representative survey data from 26
countries, and addresses the following three questions:
•

What are the major patterns and trends in medicalisation?

•

Is there an association between medicalisation and rates of change in prevalence of
FGM/C?

•

Is there an association between medicalisation and support for the continuation of the
practice?

Results show that among women ages 15-49 years, the majority (79%) report having been cut by
a traditional cutter, while an estimated 21 percent—totalling nearly 16 million girls and women—
report having been cut by a health care provider. Medicalised cutting is concentrated in three
countries; 93 percent of women who report having undergone medicalised FGM/C live in Egypt,
Sudan, and Nigeria. Elsewhere medicalised cutting is rare or restricted to geographic pockets.
Data on practitioners of FGM/C among daughters show that most cutting is carried out by
traditional cutters in all countries except Egypt and Sudan, where daughter medicalisation rates
are 78.4 percent and 77.5 percent, respectively. Mother-daughter comparisons reveal that in select
countries, rates of medicalisation are increasing—most sharply in Egypt, where the medicalisation
rate among daughters is nearly twice that of women. Successive survey data show that rising
medicalisation rates are found in countries where FGM/C rates are steady (Sudan) or dropping
(Egypt and Kenya), but overall across countries, there is no correlation between medicalisation
rates among daughters and rates of decline in FGM/C. National-level figures on medicalised
cutting of daughters are not correlated with higher support for the continuation of FGM/C. Hence,
it not clear that medicalisation undermines the ability to change attitudes against FGM/C. Nationallevel figures may mask important locally divergent factors influencing medicalisation and obscure
sub-regional associations. Hence, further focused research is needed to explore this issue.

vi

Introduction
At a United Nations summit held in 2015, world leaders adopted a new set of goals and targets
known as the Sustainable Development Goals (SDGs), outlining a development agenda for the
next 15 years. SDG target 5.3.2 calls for the elimination of all harmful traditional practices, including
female genital mutilation/cutting (FGM/C), by the year 2030. FGM/C refers to a variety of practices
involving the partial or total removal of the external female genitalia for non-therapeutic reasons.
These range from nicking the tissue surrounding the clitoris to the complete removal of the external
genitalia. WHO has classified different types of FGM/C as follows: Type I (clitoridectomy) involves
removal of all or part of the clitoris and/or the prepuce; Type II (excision) involves removal of the
clitoris and the labia minora with or without removal of the labia majora; Type III (infibulation)
involves removal of all of the external genitalia, and appositioning the labia to form a seal, leaving
a pinhole opening for the passage of urine and blood; and Type IV, all unclassified forms, including
nicking, pricking, and scraping the skin covering or near the clitoris, but no removal of tissue (WHO,
2008). FGM/C occurs in countries extending from West to East Africa, through the Horn of Africa,
and in parts of the Middle East and Southeast Asia. Surveys conducted across parts of Africa, the
Middle East, and Southeast Asia document FGM/C prevalence rates ranging from 1% (Uganda,
Cameroon) to more than 95% (Guinea and Somalia) (Shell-Duncan, Naik, & Feldman-Jacobs,
2016; UNICEF, 2016). Although survey data are lacking, FGM/C has been described in countries
including Colombia, Iran, India, Malaysia, Oman, Pakistan, Russia, and Thailand, as well as in
migrant communities throughout the world originating from countries where FGM/C is practised
(BBC, 2016; Merli, 2012; UNICEF, 1998UNICEF, 2016). It has been estimated that worldwide,
more than 200 million girls and women have undergone some form of FGM/C (UNICEF, 2016),
and more than 3 million girls are estimated to be at risk of being cut each year. A growing body of
research has documented that most forms of FGM/C can cause not only immediate health
complications such as excessive bleeding and infection, but also long-lasting genito-urinary,
obstetrical, and psychological problems (Berg, Denison, & Fretheim, 2010; Berg, Underland,
Odgaard-Jensen, Fretheim, & Vist, 2014; WHO, 2006).
Global efforts to end FGM/C have intensified over the last four decades through combined efforts
of international and non-governmental organisations, governments, religious and civil society
groups. A wide range of intervention strategies have been implemented with the goal of
accelerating abandonment of FGM/C. Initially, the most common approaches used information and
education campaigns that sought to educate people about the adverse health outcomes
associated with FGM/C. It was assumed that as people became increasingly aware of negative
health risks, they would weigh this against the perceived positive aspects, and become motivated
to abandon the practice (Muteshi & Sass, 2005). Increasingly health education campaigns were
complemented by more comprehensive strategies such as intergenerational dialogue programmes
that facilitate conversation and critical assessment of FGM/C among members of practising
communities (Muteshi & Sass, 2005), holistic community education programmes that culminate in
public declarations to abandon FGM/C (WHO, 1999), and alternative rites of passage programmes
that encourage upholding ceremonial aspects of girls’ initiation but eliminating the cutting aspect
(Chege, Askew, & Liku, 2001; Hernlund, 2000). Most, to some extent, include education on
adverse medical risks.
There has been speculation that a focus on health consequences of FGM/C may have
inadvertently led to medicalisation of the practice (Carr, 1997; WHO, 2010). An early comparative
overview of data on practitioners of FGM/C from Demographic and Health Survey (DHS) data drew
attention to the “problem” that in certain settings FGM/C was being increasingly performed by
health care providers (Carr, 1997). It also characterised declines in FGM/C prevalence as “limited
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and slow,” with the practice still supported by large segments of the population (Carr, 1997). This
has led to ongoing speculation that messaging on health risks motivated medicalisation more so
than abandonment, thereby impeding progress toward abandonment (Carr, 1997; WHO, 2010).
However, divergent views exist, with debates being centred on the question of whether
medicalisation can be a viable harm reduction strategy that can serve as a step toward
abandonment, or whether it legitimises the practice and promotes its perpetuation. During these
ongoing debates, claims about trends in medicalisation and its effect on the continuation of FGM/C
are based on limited empirical data.
Advocates of harm reduction have argued that a shift toward medicalised cutting can represent a
transitional step toward abandonment (Obiora, 1997). This shift may reflect an openness to
reassessing the way in which FGM/C is performed, including the possibility of not performing it at
all (Dawson, Homer, Turkmani, Black, & Varol, 2015; Gele, Bo, & Sundby, 2013; Modrek &
Sieverding, 2016). A study analysing the 2008 Egypt DHS data found that households were less
likely to opt for FGM/C when medicalisation was more common among their daughter’s peers; the
authors suggested that medicalisation may be associated with changing norms surrounding
FGM/C, opening possibilities for abandonment (Naguib, 2012). It is this logic that belies some, but
not all, of the policies and measures that have been instituted to minimise harm from FGM/C. In
countries such as Sudan and Somalia, trainings on FGM/C have been incorporated into the training
curriculum for health care professionals, with the goal of promoting safer and less severe forms of
cutting (Boddy, 2007; Gele et al., 2013; Gruenbaum, 1982; Kaphle, 2000; Valderrama, 2002). For
a period, policies of the ministries of health in Egypt and Indonesia issued directives for FGM/C to
be performed by health professionals (IRIN_News, September 1, 2011; Reefat, 2009). In parallel,
beginning in the 1990’s, as host countries received an increased number of immigrants from
countries where FGM/C is practised, several proposals were drafted to offer hospital-based nicking
in lieu of more severe forms of cutting (Abdulcadir, Margairaz, Boulvain, & Irion, 2011; Coleman,
1998; Obiora, 1997). Each of these proposals were met with sharp criticism and have not been
implemented.
Opposition to medicalisation is also now endorsed by professional medical organisations around
the world, including the International Federation of Gynecology and Obstetrics, which passed a
resolution in 1994 opposing the performance of FGM/C under any circumstances, in health
establishments or by health professionals (WHO, 2008). On December 20, 2012, the United
Nations General Assembly passed a Resolution on Intensifying Global Efforts for the Elimination
of Female Genital Mutilation [A/RC.3/67/L.21/Rev.1]. Its adoption reflects agreement that FGM/C
constitutes a violation of human rights, and that all countries should take action to end the practice
“committed within or outside a medical institution, and to take all necessary measures including
enacting and enforcing legislation to prohibit FGM/C and protect women and girls from this form of
violence, and to end impunity” [A/RC.3/67/L.21/Rev.1]. Currently 27 countries in Africa and the
Middle East where FGM/C is practised have banned it by law or constitutional decree (ShellDuncan et al., 2016), and in at least six of these countries (Burkina Faso, Cote d’Ivoire, Egypt,
Eritrea, Mauritania, and Senegal), the criminal code specifies an elevated penalty (prison and/or
fine) specifically for health care providers who perform FGM/C, in addition to the possibility of
suspending their licenses (Shell-Duncan, Wander, Hernlund, & Moreau, 2013).
Despite this emerging consensus, medicalised cutting is still occurring. Rates of medicalisation are
purportedly continuing to climb despite mounting criticism, scrutiny, and legal regulation (Kimani &
Shell-Duncan, 2018; WHO, 2010). Medical ethicists have argued that the unacceptably slow
progress toward abandonment justifies the endorsement of “de minimis” forms of FGM/C that do
not carry long-term medical risks (Arora & Jacobs, 2016). And soon courts of law will be asked to
adjudicate on two landmark medicalisation cases. An upcoming case in the U.S. will decide
whether medical practitioners who performed genital scraping on girls have violated a federal ban
2

on FGM/C (Belluck, 2017). While in Kenya a doctor has filed a claim that the ban on FGM/C among
adult women is unconstitutional by denying women a right to culture, to make choices about their
body, and have access to medical care should they elect to undergo this procedure (Bhalla, 2018).
Against this background, concerns remain as to whether medicalisation may be legitimising the
practice and impeding progress toward abandonment (Doucet, Pallito, & Groleau, 2017; Kimani &
Shell-Duncan, 2018). In an effort to fill this gap, we examine data on medicalisation from nationallyrepresentative survey data from 26 countries to make evidence-based inferences regarding some
key debates surrounding the effects of medicalisation. First, we explore the patterns and trends in
medicalisation. Second, to investigate the claim that medicalised cutting may slow rates of
abandonment of FGM/C, we examine association between medicalisation and rates of change in
prevalence of FGM/C, and the association between rates of medicalisation and level of support for
the continuation of FGM/C.

Methods
Data Sources
Data on medicalisation of FGM/C are available from nationally-representative data from 26
countries in Africa and the Middle East. Reliable nationally-representative data have been
generated through several major household surveys: the DHS, the Multiple Indicator Cluster
Surveys (MICS), the Egypt Health Issues Survey (HIS), and the Eritrea Population Health Survey
(PHS). Each survey asks a sample of women of reproductive age (15-49 years) about their own
FGM/C status, as well as the person who performed the cutting for those who have undergone
FGM/C. Women with at least one living daughter are asked the same questions about at least one
daughter, usually the most recently cut daughter or, in recent MICS and DHS surveys, all daughters
between ages 0-14 years. The survey also asks women their opinion as to whether the practise of
FGM/C should continue. Data were drawn from the final reports prepared for each survey. Where
data were not available in final reports, they were obtained from the publicly available data sets.

Variables
Women’s self-reported data on FGM/C come from the surveys described above. For each survey
a random sample of women aged between 15 and 49 years was drawn using a two-stage cluster
sampling procedure. Data on daughters were reported by their mothers. Data on support for
continuation of FGM/C was obtained from women who positively replied to a question about having
ever heard of FGM/C. Most surveys posed the question as “Do you think this practice should
continue? Or should it be discontinued?” This was followed by pre-coded responses: continued,
discontinued, and it depends/not sure (UNFPA-UNICEF, 2013). The number of women who
indicated they think FGM/C should continue was used to compute the percent of women who
favour continuation of the practice. Questions about practitioners of FGM/C on women or on their
daughters vary in form across surveys, and survey reports compiled categories in different forms.
In many instances data on health personnel are divided as doctor and nurse/midwife/other health
worker. Data on traditional circumcisers are often categorised as traditional practitioner and ‘other
traditional practitioner’. Some surveys have unique categories; for instance, the Egypt survey asks
about the three categories (daya, barber, and ghagarie) that are found only in the Egypt female
genital cutting module. Data from The Gambia and Yemen are reported in only two categories:
health personnel and traditional practitioners. To allow comparisons across countries, we grouped
practitioners into the two larger categories: traditional practitioners and health personnel. In the
Cameroon survey (DHS 2004), data on type of practitioner of FGM/C were collected for women,
but not daughters.
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Statistical analysis
The data reported throughout this report are weighted based on sampling design. Descriptive
statistics to facilitate comparisons across countries and to discern patterns and trends are
presented as frequencies and percentages. The outcome variables of interest are national
prevalence of FGM/C, rates of medicalisation (defined as the percent of girls and women with
FGM/C who report cutting performed by a health professional), percent of women who support the
continuation of FGM/C, and type of health personnel who performed cutting (doctor versus nurse
midwife or other health professional). For countries with consecutive surveys with comparable data
on medicalisation and prevalence of FGM/C (Benin, Burkina Faso, Chad, Cote d’Ivoire, Egypt,
Eritrea, Kenya, Mali, Niger, Nigeria, Senegal, Sudan, Togo, and the United Republic of Tanzania),
trends across time were plotted and described. The U.S. Census Bureau’s International Data Base
(U.S. Census Bureau) was used to obtain midyear population estimates by five-year age cohorts
by country for the year in which the survey data were collected. To estimate the total number of
women aged between 15 and 49 years who are cut in any one of the countries, we tally the total
number of women in this age range in the year that the most recent survey was conducted and
multiply the number by the prevalence of FGM/C among women aged 15-49 years (based on selfreported FGM/C status). The total number of women cut by health practitioners was estimated by
multiplying the total number of women cut by the medicalisation rate. Following the methods of
UNICEF (2013) we also use prevalence figures on age-specific cohorts to determine trends in
change in FGM/C prevalence. Specifically, we compare the prevalence of FGM/C in the oldest age
cohort (45-49 years) to the prevalence in the youngest age cohort (15-19 years). The percent
change between the oldest and youngest age cohorts is used to compute the rate of decline in
FGM/C. The Pearson correlation coefficient was computed between rates of medicalisation among
daughters and two different measures: 1) percent of change in the prevalence of FGM/C between
the eldest and youngest cohort, and 2) proportion of women aged 15-49 years who support the
continuation of FGM/C.

Expert group analysis
To maximise understanding of the data, the interpretation of results was done in consultation with
a panel of experts on medicalisation of FGM/C who are conducting focused studies on this topic
in their own countries. The experts interviewed were Samuel Kimani from the Africa Coordinating
Centre for the Abandonment of FGM/C (ACCAF), University of Nairobi, Kenya; Nafisa Bedri and
Yussra Mohamed from Gender and Reproductive Health and Rights Resources and Advocacy
Center (GRACe) and Ahfad University for Women, Khartoum, Sudan; Salma Abou Hussein from
Population Council in Cairo, Egypt; and Otibho Obianwu and Adetayo Adetunji from Population
Council, Abuja, Nigeria. They offered possible interpretations of the data presented in this study
based on their own research on medicalisation and offered an expert consensus on the
conclusions reached at the end of this paper. This took place during a meeting of partners involved
in the Evidence to End FGM/C: Research to Help Girls and Women Thrive research consortium,
held in Nairobi, Kenya in February and March 2018.

Results
Patterns and trends in medicalisation
Self-reported data on the prevalence of FGM/C and person who performed cutting are reported in
Table 1. The prevalence of FGM/C among women aged 15-49 ranges from as low as 1-2 percent
(Cameroon and Niger) up to 97 percent (Guinea). Among women with FGM/C, rates of
medicalisation among women aged 15-49 are highest in five countries: Sudan (67%), Egypt (42%),
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Guinea (15%), Kenya (15%), and Nigeria (13%). Elsewhere, medicalised cutting is rare and
restricted to geographically defined pockets.
Table 1. Prevalence of FGM/C, medicalisation and total number of women (age 15-49) cut by health
professionals from the most recent survey available*
Medicalisati
Total
Total
Total Cut by
Prevalence
on Among
Number of
Country
Data
Number of
Health
(%)
Women Cut
Women (15Source
Women Cut Professionals
(%)
49)
Benin

MICS 2014

9.2

0.9

2,367,594

217,819

1,960

Burkina Faso

75.8

0.2

3,688,866

2,796,160

5,592

Cameroon

MICS/DHS
2010
DHS 2004

1.4

4.0

4,098,869

57,384

2,295

CAR

MICS 2010

24.2

2.3

1,172,050

283,636

6,524

Chad

38.4

0.9

2,785,163

1,107,229

9,626

Côte d’Ivoire

DHS 201415
MICS 2016

36.7

1.0

6,117,646

2,022,276

22,452

Djibouti

MICS 2006

93.1

6.0

193,365

180,023

10,801

Egypt

HIS 2015

87.2

42.2

23,857,123

21,534,578

8,820,646

Eritrea

PHS 2010

83.0

0.3

1,289,441

869,559

3,211

Ethiopia

DHS 2016

65.2

1.0

24,091,527

15,707,676

157,077

Gambia

DHS 2013

74.9

0.3

486,629

364,485

1,093

Ghana

MICS 2011

3.8

1.2

6,041,140

229,563

2,755

Guinea

DHS 2012

96.9

15.4

2,518,996

2,440,907

375,900

Guinea-Bissau

MICS 2014

44.9

0.6

419,549

189,846

1,130

Iraq

MICS 2011

8.1

6.3

7,623,574

617,509

38,903

Kenya

DHS 2014

21.0

14.7

10,877,750

2,284,328

335,796

Mali

MICS 2015

82.7

2.3

3,807,075

3,221,836

72,414

Mauritania

MICS 2015

66.3

11.9

934,407

580,939

3,112

Niger

DHS 2012

2.0

0.0

3,423,589

68,472

0

Nigeria

18.4

12.7

42,889,199

9,787,758

939,102

Senegal

MICS
2016-17
DHS 2016

22.7

0.5

3,625,663

854,176

0

Sierra Leone

DHS 2013

89.6

1.8

1,391,263

1,246,572

13712

Sudan

MICS 2014

86.6

66.8

8,752,649

7,579,794

5,063,302

Togo

DHS 201314
DHS 201516

4.7

0.5

1,755,425

63,105

413

10.0

1.8

11,902,487

1,482,789

21,424

Tanzania
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Table 1. Prevalence of FGM/C, medicalisation and total number of women (age 15-49) cut by health
professionals from the most recent survey available*
Medicalisati
Total
Total
Total Cut by
Prevalence
on Among
Number of
Country
Data
Number of
Health
(%)
Women Cut
Women (15Source
Women Cut Professionals
(%)
49)
Yemen
DHS 2013
18.5
3.0
6,040,827
1,117,553
33,527
Total

74,326,742

26.2

15,941,674

* To calculate the total number of women cut by health professionals, data on mid-year population size of women aged
15-49 years (in the year the survey was conducted) were obtained from the U.S. Census Bureau International
Database.
CAR: Central African Republic

In the 26 countries for which we have data on medicalisation, most women with FGM/C (79%)
report being cut by a traditional practitioner; and 21 percent, totalling 15,941,674, were reportedly
cut by a health care provider. Of women who report medicalised cutting, more than half (55%)
reside in Egypt alone. Ninety-three percent of women who were cut by a health professional live
in just three countries: Egypt, Sudan, and Nigeria (Figure 1).
Figure 1. Geographic distribution of women aged 15-49 years with FGM/C who report having
been cut by a medical professional
Egypt

Sudan

Nigeria

2%

Guinea

Kenya

All other countries

2% 3%

6%

55%

32%

In 16 out of 24 countries, less than 10 percent of daughters with FGM/C were cut by medical
professionals (Figure 2). Overall, like in all women, the majority of FGM/C is most often performed
on daughters by traditional practitioners.
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Figure 2. Type of practitioner of FGM/C on daughters
Egypt
Sudan
Guinea
Djibouti
Kenya
Iraq
Yemen
Nigeria
Ghana
Mali
Benin
United Republic of Tanzania
Togo
Ethiopia
Chad
Sierra Leone
Central African Republic
Mauritania
Côte d’Ivoire
Guinea-Bissau
Burkina Faso
Eritrea
Senegal
Niger
0%

10% 20% 30% 40% 50% 60% 70% 80% 90% 100%

Health Personnel

Traditional Practitioner

DK/Missing

In eight countries, rates of medicalised cutting among daughters are 10 percent or higher (Figure
3). Comparing rates of medicalisation among mothers and daughters, rates are higher among
daughters in each of these countries except Nigeria. The trend toward increased medicalisation in
daughters, as compared to mothers, is most pronounced in Egypt, where medicalisation rates
among daughters (78%) are nearly twice those among women (42%).
Figure 3. Comparison of rates of medicalisation among mothers and daughters
100
90
80
70
60
50
40
30
20
10
0

Yemen

Djibouti

Iraq

Nigeria
Mothers

Kenya
Daughters
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Guinea

Egypt

Sudan

From the results, two categories of health professionals were identified to perform FGM/C on
daughters: 1) doctors, and 2) nurses, midwives, or other health professionals for the same
countries (i.e., Sudan, Egypt, Guinea, Kenya, Nigeria, Djibouti, and Iraq) except Yemen, where
only aggregated figures are reported (Figure 4). Egypt is unique in that doctors most commonly
undertake FGM/C. In most countries where health care providers provide FGM/C on daughters, it
is carried out by nurses, trained midwives, or other trained healthcare professionals.

Figure 4. Type of practitioner who performed FGM/C on daughters
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Association between medicalisation and change in prevalence of FGM/C
A key question is whether medicalisation counteracts efforts to eliminate FGM/C and reduces rates
of decline in FGM/C. This is a causal question for which counterfactual data do not exist; that is,
we cannot answer the question, “would rates of decline have been higher had medicalisation not
occurred?” With the data at hand, the change in prevalence of FGM/C is examined two ways: first
by computing the percent change in prevalence between the youngest (15-19 years old) and oldest
(40-49 year old) age cohorts of women, and second, by examining change in prevalence of FGM/C
in women 15-49 years across successive surveys.
Comparison of prevalence in these age cohorts are shown in Figure 5. The data show that the
prevalence of FGM/C is declining across age cohorts in all countries except The Gambia and Niger.
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Figure 5. Comparison of prevalence of FGM/C in the oldest (45-49) and youngest (15-19) age
cohorts*
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*For Ethiopia the oldest age cohort is 35-49 years because of small n.

The rate of change across cohorts is computed as the percent change in prevelance between the
oldest and youngest age cohorts. Figure 6 shows the association between the percent change in
FGM/C prevalence in the oldest and youngest age cohorts and rates of medicalisation among
daughters. The data show that the countries with the highest rates of medicalisation among
daughters (Egypt, Sudan, Guinea, and Djibouti), have a low percent change in prevalence of
FGM/C. At the same time, the country with the greatest decline in FGM/C across age cohorts,
Kenya, has a 20 percent rate of medicalisation among daughters. Low rates of medicalisation are
found in countries with widely ranging rates of change in FGM/C. Overall, there is not a significant
correlation between the rate of decline in FGM/C and medicalisation (r=-0.25, not significant).
Thus, it is not clear that motivation to seek medicalised cutting is influences by rates of
abandonment of FGM/C.
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Figure 6. Relationship between medicalisation rates among daughters and percent change in
prevalence of FGM/C between youngest (15-19 years) and oldest (45-49 years) cohorts of
women*

*Country codes: BEN – Benin; BFO – Burkina Faso; CAR – Central African Republlic; CHA – Chad; CDI - Côte
d’Ivoire; DJI – Djibouti; EGY – Egypt; ERI – Eritrea; ETH – Ethiopia; GAM – Gambia; GHA – Ghana; GUI – Guinea;
GBI – Guinea Bissau; IRA – Iraq; KEN – Kenya; MAL – Mali; MAU – Mauritania; NGR – Niger; NGA- Nigeria; SEN
– Senegal; SLE – Sierra Leone; SUD – Sudan; TOG – Togo; TAN – United Republic of Tanzania; YEM – Yemen

Members of the expert panel on medicalisation suggested that national-level figures may mask
regional variation in changes in FGM/C prevalence and medicalisation with countries, and that
local contexts and drivers of medicalisation vary substantially. For instance, in Nigeria, where Type
I FGM/C is common, medicalisation is not being driven by parents’ concerns about safety of the
practice (it is already seen as a relatively benign practice) (Obianwu, personal communication).
Instead, as women seek medicalised delivery services, FGM/C is being offered as part of routine
neonatal services (Obianwu, Adetunji, Dirisu, Ishaku, & Adebajo, 2017). By contrast, in Egypt and
Sudan, medicalisation has been linked to policies aimed at regulating harm (Bedri and Mohamed,
personal communication, Hussein, personal communication), and may entrench the practise of
FGM/C (Bedri, Sherfi, Elhadi, Rodwan, & Elamin, In preparation; El-Gibaly & Aziz, In preparation).
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Trends in prevalence of FGM/C among women aged 15-49 years and medicalisation rates among
daughters were examined through repeat survey data (available for 13 countries). Discernible
changes in medicalisation are detectable in only three countries: Egypt, Kenya, and Sudan. In
Sudan, consecutive surveys from 2010 and 2014 also revealed a sharp increase in daughters’
medicalised cutting, rising from 55 percent to 78 percent. Over this period, the prevalence of
FGM/C among women aged 15-49 years remained steady (88% to 87%). In Egypt between 1995
and 2015, rates of medicalised cutting among daughters rose sharply from 55 percent to 74
percent. During this period, the prevalence of FGM/C among women aged 15-49 years declined
from 97 percent to 87 percent. Data from Kenya shows a mixed pattern of medicalisation and
prevalence rates of FGM/C across successive surveys. There was an increasing trend to have
FGM/C performed by health care personnel (Figure 7), rising from 34 percent in 1998 to 41 percent
in 2008-09, followed by a subsequent drop in 2014. This fluctuation in medicalisation rates has
occurred simultaneously with a substantial decrease in the prevalence of FGM/C among women
aged 15-49 years, dropping appreciably from 38 percent in 1998 to 21 percent in 2014. However,
these data do not allow us to test causal associations nor whether the decline in FGM/C might
have been even larger if health professionals were not performing FGM/C. Nonetheless, the results
for Kenya indicate that medicalisation rose whilst FGM/C prevalence fell. The expert panel member
from Kenya (Samuel Kimani) suggested that this pattern may be attributable to the fact that in
Kenya, decreases in the prevalence vary dramatically along lines of ethnicity, and medicalisation
is concentrated in communities that have been resistant to abandoning FGM/C (Kimani & Kabiru,
In preparation; Shell-Duncan, Gathara, & Moore, 2017).

Figure 7. Trends in prevalence of FGM/C and medicalisation in Kenya
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Association between medicalisation and support for the continuation of FGM/C
A related question is whether medicalisation influences support for the continuation of FGM/C. It
has been posited that the availability of medicalised cutting may lead to continued support for
FGM/C by creating the impression that it can be performed safely. Alternatively, mothers who opt
for medicalised cutting for their daughters may be persuaded about the harmfulness of FGM/C and
may be more likely to favour abandonment.
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Women’s self-reported support for the continuation of FGM/C ranges from as high as 72 percent
in Mali to as low as 1.5 percent in Ghana. Figure 8 plots the percentage of women who support
the continuation of FGM/C against rates of medicalisation among daughters. The results show that
there is not a significant correlation between medicalisation and higher support for continuation of
FGM/C (r=0.50, not significant). This finding may also be linked to the fact that there is tremendous
variation in factors motivating medicalisation and is not universally linked to concerns about health
risks (expert panel and Kimani & Kabiru, in preparation; Obianwu et al., 2017).

Figure 8. Relationship between medicalisation rates among daughters and the proportion of
mothers who support the continuation of FGM/C*

*Country codes: BEN – Benin; BFO – Burkina Faso; CAR – Central African Republlic; CHA – Chad; CDI - Côte d’Ivoire; DJI –
Djibouti; EGY – Egypt; ERI – Eritrea; ETH – Ethiopia; GAM – Gambia; GHA – Ghana; GUI – Guinea; GBI – Guinea Bissau; IRA
– Iraq; KEN – Kenya; MAL – Mali; MAU – Mauritania; NGR – Niger; NGA- Nigeria; SEN – Senegal; SLE – Sierra Leone; SUD –
Sudan; TOG – Togo; TAN – United Republic of Tanzania; YEM – Yemen
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Discussion
This study draws on population-based survey results from 26 countries and the perspectives of
members of the expert panel conducting focused studies on the medicalisation of FGM/C. Findings
from the study reveals an estimated 21 percent of women with FGM/C had the procedure
performed by a health care provider (doctor, nurse, trained midwife, or other health professional),
while the majority (79%) reported being cut by a traditional circumciser. All told, nearly 16 million
girls and women experienced medicalised cutting. Medicalised cutting is highly concentrated
geographically. Of women who report having been cut by a health care provider, more than half
(55%) live in Egypt alone. Overall, 93 percent of women who reportedly experienced medicalised
cutting live in Egypt, Sudan, and Nigeria. Elsewhere, medicalisation is rare or restricted to
geographic pockets. Comparing medicalisation rates between survey respondents and their
daughters, rates of medicalisation are increasing sharply in both Egypt and Sudan, but not in
Nigeria.
Egypt appears to be unique in terms of being the only country in which medicalised cutting is
carried out primarily by doctors, as opposed to nurses or other health workers. This trend is
historically linked to health policies from the 1990’s. In an effort to reduce the harm of what was
viewed as an inevitable practice, the Ministry of Health issued a decree that lifted a 35-year ban
on performing FGM/C in public hospitals in 1994 (El-Gibaly, Ibrahim, Mensch, & Clark, 2002). The
Ministry asked state hospitals to set aside one day a week for performing FGM/C “by trained
physicians under hygienic conditions” (Reefat, 2009). This policy came under sharp criticism, was
reversed to banning FGM/C in both state and private hospitals. A “loophole”, however, allowed for
“medically necessary circumcision,” (Modrek & Liu, 2013) and was not closed until 2007 by a
Ministerial Decree prohibiting doctors, nursing staff, or others from performing FGM/C, whether in
governmental or non-governmental hospitals. This decree was bolstered by the adoption of a 2008
law making FGM/C a crime punishable by imprisonment or fine. In January 2015, the first
successful FGM-related prosecution took place, convicting a doctor of involuntary manslaughter
for his role in the death of a 13-year-old girl and sentencing him to two years and three months in
prison (Michaelson, 2016). In 2016, the law banning medical professionals from performing FGM/C
in either state or privately-run clinics was amended to raise the maximum sentence from three to
15 years in prison (Sirgany, 2016).
In Sudan, where 67 percent of women with FGM/C report having undergone medicalised cutting,
the procedure is in most instances performed by trained midwives. During the colonial era,
government officials introduced measures intended to reduce the harm of infibulation by restricting
the severity of cutting. Knowing that traditional birth attendants were the primary providers of
FGM/C, midwifery schools established in Sudan in the 1920’s taught a modified or “intermediate”
(mitwasit) form of cutting that involved the same amount of cutting, but less stitching (Boddy, 2016).
In 1946, a law was passed banning infibulation but allowing less severe forms of cutting. The law
was ratified in 1956 when Sudan became independent but was dropped from the 1983 Penal Code.
Although the Sudanese Medical Council has now banned FGM/C by any medical professional
(Sharfi, Elmegboul, & Abdella, 2013), there is no national law regulating FGM/C or medicalisation.
Currently, WHO is conducting trials of interventions aimed at de-medicalisation of FGM/C in two
states (Ahmed, 2017; Bukuluki, 2017). Such investigations are needed, as it is unclear how demedicalisation might influence strategies aimed at abandonment of FGM/C. One recent study in
Egypt found that when a daughter’s peers had undergone medicalised FGM/C, her own likelihood
of being cut was in some instances reduced. The author suggests medicalisation may reflect
shifting social norms that open change possibilities, including abandonment of FGM/C (Naguib,
2012). Whether this is also true in Kenya is unclear (Kimani & Kabiru, In preparation).
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In Nigeria, girls and women who have experienced medicalised cutting are in most cases
reportedly cut by nurses (Ashimi, Aliyu, Shittu, & Amole, 2014; Obianwu et al., 2017). A recent
qualitative study in Nigeria questions how often these providers are formally trained nurses or
informally trained auxiliary nurses or midwives (Obianwu et al., 2017). It also showed that
medicalisation is not driven primarily by harm reduction concerns, as it is widely considered to be
a relatively benign procedure; instead it appears to be linked to an uptake in labour and deliver
services in centres that offer FGM/C as part of routine neonatal care options (Obianwu et al., 2017).
Findings from the study also indicate that there is no significant correlation between rates of
medicalisation among daughters and rates of decline in prevalence of FGM/C at the national level.
Further multivariate analyses are needed to control for potentially confounding factors and account
for subnational variation. Repeat survey data on medicalisation among daughters are available for
13 countries, and substantial changes in medicalisation are found in Egypt, Kenya, and Sudan. In
Egypt and Kenya, medicalisation has occurred alongside declines in rates of FGM/C. At the same
time, Sudan shows persistently high rates of FGM/C alongside rising medicalisation rates. Whether
medicalisation is hindering this decline is unclear but can be addressed in focused research.
Debates have also centred on whether medicalisation legitimises the practise of FGM/C by
creating an impression that the procedure may be performed safely, or whether parents who opt
for medicalised cutting may be more open to change in FGM/C and less likely to support
continuation of the practice (Dawson et al., 2015; Modrek & Sieverding, 2016; Naguib, 2012). To
investigate these claims, we examined the association between rates of medicalisation among
daughters and mothers’ stated support for the continuation of FGM/C and found no significant
correlation.
There are a number of limitations in this study. We examined trends and correlations, which may
be influenced by outliers, and as such further multivariate analyses are needed to control for
potentially confounding factors, and to examine within-country patterns. Moreover, there are some
concerns regarding the validity of the survey data used in this study. Self-reported data on FGM/C
need to be treated with caution as inaccuracies may arise because of unwillingness to disclose
having undergone FGM/C due to the sensitivity of the topic or because of criminalisation of the
practice (Askew, 2005; Shell-Duncan, 2017). Additionally, particularly when FGM/C is performed
at an early age, women may be unaware of whether they have been cut or the extent of the cutting
or may not accurately recall the circumstances surrounding the procedure. A number of studies
have attempted to determine the reliability of self-reports of FGM/C status (being cut or not) by
verifying them through clinical examinations, and have reported variable rates of concordance
(Adinma, 1997; Elmusharaf, Elhadi, & Almroth, 2006; Klouman, Manongi, & Klepp, 2005; Morison,
Dirir, Elmi, Warsame, & Dirir, 2004; Msuya et al., 2002; Snow, Slanger, Okonofu, Oronsaye, &
Wacker, 2002). The general consensus is that self-reports of being cut or not provide reasonably
reliable estimates of FGM/C prevalence (Yoder & Wang, 2013).

Conclusion
Among girls and women aged 15-49 who have undergone FGM/C, 21 percent have been cut by
professional health care workers. For those working to deter or prevent medicalised cutting, it is
important to recognise that it is concentrated in three countries namely Egypt, Sudan, and Nigeria.
Mother-daughter comparisons indicate that medicalisation rates are increasing in several
countries, most sharply in Egypt where rates have more than doubled. Further studies are needed
to understand the rationale for selecting medicalised cutting, and whether or how medicalisation
influences readiness to change FGM/C. The data do not show a significant association between
medicalised FGM/C among daughters and rates of decline in prevalence of or support for the
continuation of the practice. An expert panel on medicalisation suggested that it is likely that
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national-level figures mask important subnational variation in changes in FGM/C prevalence and
medicalisation rates, as well as differences in factors driving medicalisation. Rising rates of
medicalisation occur alongside both modest declines in FGM/C (in Egypt) and substantial declines
in FGM/C (Kenya). In Sudan, medicalisation rates rose while the prevalence of FGM/C remained
steady. Whether medicalisation is hindering abandonment of FGM/C is unclear. The question
remains as to whether this shift represents reluctance to stop an intractable practice or signifies
openness to change that can be leveraged to promote abandonment. This is a pressing matter
that influences actions needed to achieve the international community’s recently adopted set of
SDGs, including target 5.3.2 calling for the elimination of all harmful traditional practices such as
FGM/C by 2030. Further focused research taking into account local contexts is needed to address
this issue.
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